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Katherine A. Abrahams and Gurdyal S. Besra *
Mycobacterium tuberculosis is the causative pathogen of the pulmonary disease tuberculosis. Despite the
availability of effective treatment programs, there is a global pursuit of new anti-tubercular agents to
respond to the developing threat of drug resistance, in addition to reducing the extensive duration of
chemotherapy and any associated toxicity. The route to mycobacterial drug discovery can be considered
from two directions: target-to-drug and drug-to-target. The former approach uses conventional methods
including biochemical assays along with innovative computational screens, but is yet to yield any drug
candidates to the clinic, with a high attrition rate owing to lack of whole cell activity. In the latter approach,
compound libraries are screened for efficacy against the bacilli or model organisms, ensuring whole cell
activity, but here subsequent target identification is the rate-limiting step. Advances in a variety of scientific
fields have enabled the amalgamation of aspects of both approaches in the development of novel drug
discovery tools, which are now primed to accelerate the discovery of novel hits and leads with known
targets and whole cell activity. This review discusses these traditional and innovative techniques, which are
widely used in the quest for new anti-tubercular compounds.
Introduction
Mycobacterium tuberculosis (Mtb), the etiological agent of
tuberculosis (TB), is the leading cause of death from a single
infectious agent and ranks in the top ten causes of death
worldwide. Despite innovations in diagnostics, treatment
programs and healthcare provision, in 2019, this largely
treatable disease infected an estimated 10 million people and
was responsible for approximately 1.4 million deaths.1 The
global burden of this disease is augmented by multi-drug
resistant (MDR) and extensively-drug resistant (XDR)-TB
strains, which continue to threaten the efficacy of treatment
strategies and this drives the demand for the discovery of new
anti-tubercular drugs to complement existing regimens.2
Presently, there are twenty-three anti-tubercular drug
candidates in clinical trials and combination programs for
the effective treatment of drug-susceptible, MDR and latent
Mtb strains.1 However, continuous and concerted efforts from
multiple research disciplines is paramount in the
development of new clinical drug candidates, which remains
at the forefront of this on-going global battle against TB.
Various considerations direct the development of new
anti-tubercular agents. These compounds ideally need to be
affordable, compatible in combination therapies, reduce the
treatment duration (currently 6 months minimum) and have
a low mutation frequency of resistance.3 They also need to
exhibit low toxicity over long time periods with minimal side-
effects or drug interactions.1 In addition, to these desirable
characteristics, the discovery of novel hits and leads against
Mtb alone poses an inherent challenge. Mtb has a slow
growth rate, which negatively impacts the rate of research.
Drugs targeting Mtb need to be active in different phases of
infection; Mtb can exist in diverse microenvironments
(including macrophages and granulomas),4 as well as in
physiologically distinct sub-populations: replicating (aerobic
conditions) and non-replicating (anaerobic conditions), as
well as resistant and persistent states.5,6 Adding to the
challenge of anti-tubercular drug discovery is the
distinguishing feature of mycobacteria, an expansive and
adaptable cell wall.7 This macromolecular structure is
essential for survival and pathogenesis and serves as a
permeability barrier, protecting the bacilli against
hydrophilic compounds.8 It is therefore unsurprising that
two of the drugs in mainstay TB treatment and others
progressing through clinical trials, target the synthesis of key
cell wall components.9,10 Over the past decade, developments
in genomic and molecular techniques, including valuable
insights gained from whole genome sequencing (WGS),11 has
advanced our understanding of the biochemistry and
pathogenicity of Mtb, facilitating the exploration of
chemotherapeutic agents targeting novel cellular processes.
Despite this, less than 0.5% of Mtb proteins are exploited in
current treatment strategies,12 exemplifying the goldmine of
unexploited targets. This review explores the diverse
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techniques in mycobacterial drug discovery with an ultimate
outlook: a combined response from distinct areas of




Research into the discovery of novel anti-tubercular drugs
requires a concerted response from a diverse range of fields
including biochemistry, microbiology, structural biology and
chemistry, informatics, physical and organic chemistry to
name but a few. The drug discovery paradigm has to
continuously adapt in response to technological advances in
these fields whilst complementing traditional techniques. In
the drug discovery pipeline, target identification, although
not always possible, is a valuable step and can determine the
suitability of whether a compound can progress into a pre-
clinical drug candidate.13 Therefore, drug discovery can be
approached from two main angles: target-to-drug14 or drug-
to-target,15 and advances in scientific innovations dictate the
equilibrium in favour of either directive, which is in constant
flux. In target-based drug discovery, in vitro or in vivo,
compounds are screened or developed against a pre-
determined metabolic process or enzyme. This ensures target
suitability, such as those lacking human orthologues, those
with no known pre-existing drug resistance, favourable
localisation (e.g. on the extracellular surface), and for many
more reasons. However, the whole cell activity of the
compound requires verification, and failure to establish this
contributes to the high attrition rate in target-based drug
discovery. In contrast, the drug-to-target approach benefits
from confirmed whole cell activity of the compound, but the
target requires subsequent identification. This is a
challenging process that could transpire an unfavourable or
uncharacterised mode of action and often results in the
rediscovery of inhibitors targeting a small subset of
‘promiscuous’ targets, such as MmpL3 or DprE1.16 MmpL3 is
responsible for transporting trehalose monomycolate across
the plasma membrane for cell wall biosynthesis.17,18 DprE1 is
also involved in cell wall biosynthesis, generating the lipid-
linked arabinose precursor of the arabinan cell wall
component.19 The high ‘hit rates’ from screening campaigns
of these drug targets can be rationalised by their plasma
membrane location, making them accessible to inhibitors.20
There is an impetus towards the complementary use of the
target-to-drug and drug-to-target approaches, to benefit from
the advantages and alleviating the pitfalls of each,
accelerating the discovery of new drug candidates.
Drug-to-target inhibitor discovery
and target identification
Over recent years, high-throughput screens (HTS) of extensive
compound libraries have changed the fortune of TB drug
discovery efforts, unearthing a plethora of diverse inhibitory
molecules.21 With hundreds of thousands of drugs available,
phenotypic whole cell HTS have been used to rapidly identify
inhibitors of Mtb.22,23 These screens commonly employ the
microplate alamar blue assay to assess drug susceptibility
(Fig. 1A),22–25 but alternative methods such as monitoring cell
growth through the heterologous expression of a fluorescent
marker can be an alternative approach.26,27 The screens can
be modified to mimic the different physiological states of
Mtb during infection, such as aerobic and anaerobic
conditions,28,29 starvation,30 in addition to the requirement
of different carbon sources and nutrients31,32 and in
Mtb-infected macrophages.33,34 The phenotypic-based hits
discovered from these screens already circumvent
permeability issues and can be further assessed for
additional criteria including cytotoxicity, ultimately providing
compounds with good selectivity and specificity. In hit-to-
lead optimisation, target validation is a crucial proceeding
step (Fig. 1B). WGS of laboratory-generated spontaneous
resistant mutants is routinely used to identify mutations
within the target gene, which enables the resistance
phenotype.35–38 Target identification in this way is not always
possible, with examples including: 1) if mutations occur in
genes responsible for the resistance mechanism, such as the
up-regulation of efflux pumps39 or mutations in pro-drug
activators;40,41 2) if there is more than one target;42 3) if the
target is not a protein (such as the cell wall structural targets
of nisin and vancomycin); 4) if spontaneous resistant mutant
generation is not possible. In these circumstances, target
deconvolution becomes a challenging process, but not
impossible.
RNA sequencing is a valid technology in target
elucidation, where analysis of the transcriptome following
drug treatment can reveal changes to the expression levels of
genes (target, pathway, or compensatory). This technique is
especially useful if resistant mutants harbour mutations in a
gene encoding a transcriptional regulator. Transcriptional
profiling of delamanid of phase III clinical trials has provided
insights into its mode of action.43 Although delamanid has
been shown to inhibit cell wall synthesis,44 the expression of
genes coinciding with this process was negligibly impacted.
Contrarily, genes responding to the effects of respiratory
poisoning were up-regulated, suggesting a cause of the
bactericidal activity of delamanid, although the exact mode
of action remains to be determined.43 RNA sequencing can
therefore be used to facilitate target delineation.
Chemoproteomic strategies are becoming commonplace
in target identification or validation. In this technique,
tagged inhibitor analogues are linked to Sepharose beads,
and incubated with cell extracts in the presence and absence
of inhibitor. In this competitive binding strategy, the target
protein is expected to predominantly bind to the inhibitor-
linked beads in the absence of inhibitor. Following bead
washing and tryptic digestion, quantitative mass
spectrometry analysis can be used to distinguish between
proteins generically binding to beads, and those that are
competitively bound. This technique is not suitable for
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identifying targets that are not proteins, or proteins that are
unstable. Also, steric hindrance of the tagged analogue may
prevent target binding. However, chemoproteomics can be
used to directly establish target engagement and this
technique was used to identify EchA6 as the target of the
tetrahydropyrazo[1,5-a]pyrimidine-3-carboxamide
compounds,45 and to validate KasA as the target of an
indazole sulphonamide.35
Metabolomics is emerging as a key tool in mode of action
studies and metabolic analysis before and after drug
treatment can reveal changes in the metabolome, which can
be correlated to the inhibited metabolic pathway. However, a
requirement of this technique is that the target or pathway
have known functions or that the inhibitor's mode of action
correlates with existing drugs for comparative purposes. For
example, Zampieri et al., (2018) have performed a high-
throughput metabolomics analysis on Mycobacterium
smegmatis treated against a library of compounds.46 The
metabolomic responses were compared with the metabolome
profiles of M. smegmatis treated with drugs with known
targets. Using this strategy, 70% of the compounds analysed
induced responses corresponding to that of known modes of
action, facilitating the delineation of the specific targets of
these compounds.46
Fig. 1 Whole cell phenotypic screening and target identification. A) Drug-to-target drug discovery generally exploits whole cell phenotypic
screening, which involves the incubation of a mid-log culture of mycobacteria with a library of compounds at a specified concentration (usually
10–20 μM), in a multi-well plate format to allow for high-throughput. Cell viability can be established by the microplate alamar blue assay, where a
non-fluorescent resazurin (blue) is reduced to a fluorescent resorufin (pink) by living cells. B) Following the discovery of an anti-tubercular
compound, various methods can be used to establish the target. These include spontaneous resistant mutant generation against the compound
followed by (i) WGS to identify resistance conferring mutations, or (ii) changes in gene expression profiles, such as the up-regulation of the target
gene. Alternatively, mass spectrometry can be exploited: (iii) in a chemoproteomics approach, inhibitor-bound matrices can be used to pull down
competitively binding proteins from a cell lysate; (iv) metabolomic analysis of drug-treated cell culture can be used to identify changes to the
metabolome, for example the reduction of a product from an inhibited pathway. In morphological profiling (v), cells are treated with drugs that
have known and unknown modes of action and the morphological features analysed. Comparisons of the two groups can reveal target pathways.
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Morphological profiling is a new tool that has been
developed to identify target pathways (DNA synthesis, RNA
synthesis, protein synthesis, cell wall synthesis, respiration)
of anti-tubercular agents.47 In this approach, a platform,
morphological evaluation and understanding of stress
(MorphEUS), can be used to classify targets based on imaging
features such as cell shape, nucleoid shape and staining
intensity. This new technique was applied to 34 anti-
microbials with known modes of action, grouping the
majority of them to their target pathway, highlighting the
success of this application for mode of action elucidation.47
These target identification approaches can be used in
parallel with other biochemical characterisations, including
kinetic and binding assays and co-structural
determinations, to validate the target. However, although
favourable for the prioritisation and progression of
compounds into pre-clinical drug candidates, target
identification is not necessarily essential, if for example, a
compound exhibits encouraging characteristics in terms of
efficacy and cytotoxicity profiles. This is true for the
inhibitors, delamanid44 and pretomanid,48 which are
completing phase III clinical trials;1,49 there is evidence to
suggest these pro-drugs have a multifaceted approach
upon activation, targeting mycolic acid biosynthesis under
aerobic conditions and release reactive NO species under
anaerobic conditions, causing respiratory
poisoning.43,44,48,50,51 Further evidence reveals that upon
drug treatment, there is an accumulation of a toxic
metabolite, methyl glyoxal, resulting from the build-up of
sugars in the pentose phosphate pathway, suggesting an
alternative mechanism of killing by these pro-drugs.52
Given the therapeutic potential of these drugs, the
specificities of the inhibition mechanism could prove
valuable in the further optimisation of these compounds.
Drug-to-target whole cell phenotypic HTS of inhibitor
libraries have yielded a number of drug candidates
(delamanid,44 pretomanid,48 SQ109,53 Q203,34 bedaquiline54)
that are currently progressing through clinical trials1 (Fig. 2).
This exemplifies the success of whole cell screening in drug
discovery.
Target-to-drug inhibitor identification
For target-based drug discovery, the landmark achievement
of the sequencing of the Mtb genome has accelerated the
discovery of new potential drug targets, with known,
predicted and unidentified activities. The essentiality of Mtb
genes, originally assessed using transposon site hybridization
(TraSH), are now commonly determined by deep sequencing
based approaches such as transposon sequencing (Tn-seq).
In the TraSH method, a pool of transposon insertion mutants
are generated, where a single Himar1 transposon inserts into
the dinucleotide TA, which are present approximately every
60 bases in the Mtb genome.55 Strains where essential genes
have been disrupted by transposon insertion will be absent
from the pool of transposon mutants. The surviving strains
contain mutations in non-essential genes, which can be
detected through probe generation and microarray
hybridisation.55,56 In a similar approach, Tn-seq combines
the generation of transposon insertion mutants with
massively parallel sequencing, enabling the precise location
of the insertion to be mapped onto the genome sequence.57
Large pools of transposon mutant strains have been analysed
to identify genes that are essential for growth under different
conditions.56,58,59 However, transposon mutagenesis has
limitations for target discovery, including: 1) genes lacking
the TA dinucleotide cannot be analysed; 2) site specificity
renders 9% TA sites less permissible to transposon insertion
Fig. 2 Drug candidates identified from whole cell HTS. The structures of A) delamanid, B) pretomanid, C) Q203, D) SQ109 and E) bedaquiline are
shown, which are currently progressing through clinical trials.
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leading to approximately 1% of genes to be falsely classified
as essential in the TraSH methodology; 3) transposon
insertions into non-essential regions in or adjacent to
essential genes could falsely classify the gene as non-
essential; 4) insertions into operons can impact downstream
activity; 5) the essentiality of genes is determined in vitro,
which may not be relevant during infection.55,56,58,59 Based
on these limitations, caution must be taken when selecting a
target based on its predicted essentiality. Examples include
PBPA and RodA, a transpeptidase and transglycosylase,
respectively, with roles in peptidoglycan synthesis60 and
RipA, a D,L-endopeptidase involved in peptidoglycan
remodelling.61 These enzymes exhibit differences in
essentiality in vitro versus in vivo. Additionally, genes
classified as non-essential by TraSH, such as the catalytically
inactive enoyl-CoA hydratase EchA6,45 have been shown to be
essential. Other developments in molecular biology
techniques have been beneficial in the study of gene
essentiality. For example, knock-out studies, including
anhydrotetracycline-inducible gene expression systems,62
allow gene essentiality to be established in vivo during
different stages of infection,63 enabling the validity of a target
to be confirmed.
With the ever increasing availability of biomedical data,
for example from gene expression profiles and proteomics,
data mining has further led to an increase in the
identification of valid targets. The selection of a gene for
target-based drug discovery efforts ultimately requires the
druggability of the target to be confirmed (essentiality,
redundancy, vulnerability during infection, homology to
human proteins, mutation rates, activity during dormancy, to
address a few criteria).14 This is to avoid wasting copious
time and resources focusing on the development of
inhibitors against an unsuitable mode of action. In TB drug
discovery, validated druggable targets equate to a very small
number, exemplifying the need for new targets to circumvent
problems associated with the treatment of MDR and XDR-TB.
To advance the discovery of novel putative targets, an
Mtb-specific protein druggability database (TuberQ) has been
developed.64 Using information from unique Mtb structures
and homology-based models, the structural druggability of a
given protein is determined through the identification and
analysis of putative inhibitor binding pockets. This data is
combined with the physiological relevance of proteins (gene
essentiality and expression under different stress conditions),
enabling the rapid inspection of target suitability based on
the structural and biological druggability of a chosen
protein.64 This tool, therefore, is highly valuable in target-
based drug discovery.
Conventional target-based drug discovery typically
employs the development of in vitro biochemical assays that
demonstrate biological activity. The assays rely on the
availability of purified recombinant protein and suitability of
substrates (or appropriate analogues) or products for kinetic
characterisation in the presence of potential inhibitors.
Technological developments over the past two decades have
enabled the adaptation of single biochemical assays into a
high-throughput format, for the rapid analysis of compound
libraries. Modern target-based drug discovery techniques
exploit the recent advances in 3D-structural determinations,
courtesy of X-ray crystallography, nuclear magnetic resonance
(NMR), and cryogenic electron microscopy (cryo-EM), in
addition to computational or in silico analytical methods,
which have facilitated the rational design of inhibitors or
virtual screening of compound libraries against the target.65
Both of these methods can be divided into either structure-
based or ligand-based, searching for inhibitors against the
target active site or similarities with the known ligand,
respectively (Fig. 3). For example, inhibitors of Mtb
dihydrofolate reductase have been identified by two distinct
ligand-based approaches and complemented by a structure-
based approach (DHFR).66 Other structure-based approaches
include the discovery of new inhibitors of InhA and DprE1,
enzymes involved in cell wall biosynthesis.67,68 In silico
studies are valuable not only in the search of new inhibitors,
but also in the structural optimisation of existing drug
candidates to improve pharmacokinetic and
pharmacodynamic properties. These techniques can provide
a vast quantity of potential inhibitors. However, the attrition
rate for target-to-drug based inhibitor discovery is high,
owing to problems associated with drug entry into the cell,
toxicity, poor pharmacokinetic properties, and complex
synthetic pathways. Screening compounds with known
inhibitory activity against Mtb can alleviate some of these
difficulties.
Fragment-based drug discovery is another useful tool in
the identification of target-specific small molecule inhibitors.
In this approach, a library of diverse fragments, often
developed by computer simulations for a selected target, is
screened against a target protein. Various techniques can be
used to determine fragment interaction with the target
protein, including differential scanning fluorimetry,69
Fig. 3 In silico drug discovery. Structure-based or ligand-based drug
discovery involves the computational screening of a compound
database against the protein target structure (e.g. active site) or the
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saturation transfer difference (STD)-NMR,70 and surface
plasmon resonance,71 in addition to the more traditional
biochemical assays. For example, a 1360 fragment library has
been screened against NADH-bound InhA. Primarily, STD-
NMR was used to identify fragment binding, and hits were
then further confirmed through biochemical assay and
SPR.70 Fragments from such screens can be further
developed into lead compounds.
Combining drug-to-target and
target-to-drug approaches
Innovative strategies are being developed to combine the
advantages of drug-to-target and target-to-drug approaches
and to circumvent any pitfalls. Target-based whole cell
phenotypic HTS enable the rapid, simultaneous discovery of
new whole cell-active inhibitors with known modes of action.
An example is the use of mycobacteria over-expressing a
target gene, which can be used to screen compound libraries
(Fig. 4A); increased resistance to a compound signifies target
engagement, where the additional target protein or enzyme
can compensate for the inhibition of that of the native
activity, or alternatively the additional target can saturate
with inhibitor, enabling the native protein to function. This
technique is exploited in drug discovery and target validation
strategies. For example, the over-expression of DprE172 and
GuaB2 (inosine monophosphate dehydrogenase)73 have led
to the discovery of novel inhibitors specifically targeting these
enzymes; over-expression studies of KasA (β-ketoacyl
synthase),35 QcrB36 (subunit b of the cytochrome bc1
complex) and TrpAB (tryptophan synthase) have confirmed
target engagement as predicted by WGS of resistant
isolates.37
A relatively new tool with applications in target-based
whole cell phenotypic screening is clustered regularly
interspaced short palindromic repeat interference
(CRISPRi),74 which enables the tuneable knockdown of
proteins by interfering with gene transcription (Fig. 4B) and
is applicable for both essential and non-essential genes. In
this system, a small guide RNA, specific to the target gene
promoter region or open reading frame, simultaneously
binds to the genomic DNA and to a catalytically dead form of
RNA-guided DNA endonuclease (dCas9), which results in a
complex that interferes with the transcription of the target
gene through steric hindrance. Through the temporary
suppression of gene transcription, and ultimately the
expression levels of the target protein, it is possible to analyse
the impact of the gene, both in vitro and in vivo. This allows
the suitability of the expressed protein as a drug target to be
established, and can also be used to determine whether drug
effects are mimicked, enabling predicted drug targets to be
validated. Reduction of gene expression levels in the presence
of inhibitors can reveal target-inhibitor relationships in a
similar manner to the over-expression studies, but with the
opposite result: limiting target gene expression increases
sensitivity to the inhibitor.
Another exciting chemical-genetics tool has been
developed for concomitant discovery of inhibitors and their
target. This approach regulates gene expression through the
specific degradation of tagged-proteins by caseinolytic (Clp)
proteases. Johnson et al. (2019) have recently optimised this
approach for the high-throughput screening of compound
libraries against large pools of tagged proteins (Fig. 4C).75
Briefly, a DAS-tag and a unique barcode are introduced on to
the 3′ end of a gene, creating a hypomorph, pools of which
can be generated. The inducible and tuneable expression of a
vector encoded stringent starvation protein B (SspB) shuttles
the tagged target protein to a Clp protease where it is
degraded. Upon exposure to a library of compounds,
inhibitors targeting a specific hypomorph strain within a
pool can be identified through barcode counts, where a
decrease in signal signifies increased sensitivity to drug
treatment.
Computational innovations combining structural
bioinformatics, molecular modelling and systems biology can
be used to identify drug–target interaction networks. For
example, Kinnings et al. (2010) have integrated these
computational strategies to construct a drug–target network,
identifying drug–target interactions between the known
structural proteome of Mtb with structurally characterised
approved drugs.12 The rational behind this work was to
identify novel pharmaceutical targets and concomitantly
repurpose known drugs to treat TB, alleviating the time and
investment in developing novel compounds.12 This network
can be exploited in the analysis of any new approved drugs,
with the potential to rapidly progress drugs through the drug
discovery pipeline. The in vivo efficacy of these drugs,
however, remains to be assessed, but can be circumvented by
testing the approved library prior to screening. Alternatively,
‘hits’ can be re-engineered to improve potency. For example,
the approved laxative and osteoarthritis compound rhein
exhibits anti-microbial activity, but not against Mtb. To
circumvent potential issues with target accessibility, the rhein
scaffold has been successfully re-engineered to increase
lipophilicity (enabling permeation of the hydrophobic cell
wall), dramatically improving potency.40
With the extensive quantities of publicly available data
generated from drug screening programs, in vivo and in vitro,
machine learning models are rapidly being developed for data
curation.76 These models can be used to prioritise compounds
for drug discovery efforts, predicting molecules that combine
activity with suitable physiochemical and pharmacokinetic
properties. Machine learning can also be applied for mode of
action determination, based on known drug-target interactions,77
as well as for the predication of resistance conferring
mutations.78 The machine learning models are developed with
the aim of increasing the efficiency of drug discovery.
Inhibitor and target validation
Irrespective of whether an inhibitory compound has been
identified through a drug-to-target or target-to-drug
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Fig. 4 Drug discovery techniques combining drug-to-target and target-to-drug approaches. A) Target-based whole-cell phenotypic screening. In
this technique, a compound library is screened against cells over-expressing a target protein (from a mycobacterial vector). Assessing cell viability
at a fixed drug concentration enables the comparison of drug sensitivities between strains with and without the over-expression of the target
protein and can reveal inhibitor-target engagement. B) Target protein knockdown by CRISPRi. In this approach, target protein expression is
reduced by interfering with the transcription of mRNA. Anhydrotetracycline (ATc) regulates the transcription of a small guide RNA (sgRNA) and a
catalytically dead endonuclease, dCas9. The sgRNA contains a short complementary sequence to the target gene and a region for dCas9
recognition. A proto-spacer adjacent motif (PAM) is essential for dCas9 binding. The sgRNA–dCas9 complex anneals to the target sequence,
adjacent to PAM, blocking transcription by RNA polymerase, and depleting the expression of the target protein. C) Target protein knockdown by
protease degradation allows the reduction of a specific protein through targeted degradation. In this specific approach, a degradation tag (DAS)
and a barcode are integrated onto the 3′ end of the target gene. ATc drives the expression of SspB, which recognises the DAS tag and shuttles the
protein to a Clp protease. In a drug screen, a strain will exhibit increased inhibitor sensitivity if the degraded protein is the drug target. The specific
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approach, the alternative strategies described can
additionally be used to complement findings and validate a
compound's mode of action. For example, it is commonplace
to identify the target of a compound through WGS of
resistant isolates, with an accompanying mode of action
confirmation through an unexhaustive list of techniques,
including biochemical and binding assays, over-expression
studies, chemoproteomics and 3D structural information, to
mention a few. This evidence in turn, can be used to direct
medicinal chemistry efforts to optimise the compound
structure (potency, toxicity, physiochemical and
pharmacokinetic properties) based on structure–activity and
structure–property relationships. The compounds can then
be re-analysed to confirm target engagement. For example,
an indazole sulphonamide from a GlaxoSmithKline directed
phenotypic screening campaign22,23 had attractive properties
for early stage drug discovery based on its potency and
in vitro and in vivo profiling.35 Consequently, this compound
was subject to target identification efforts.35 Initially, WGS of
resistant isolates in both Mtb and Mycobacterium bovis BCG
revealed SNPs in kasA, which encodes the essential β-ketoacyl
synthase involved in the biosynthesis of mycolic acids, which
are major components of the Mtb cell wall. Target validation
techniques subsequently confirmed target engagement of the
compound with KasA. Radioactive biochemical assays were
performed with whole cells and confirmed the dose-
dependent depletion of α- and keto-mycolic acid methyl
esters consistent with the inhibition of mycolic acid
biosynthesis. In a second radioactive biochemical assay using
purified recombinant protein, the specific inhibition of
recombinant KasA activity was demonstrated. M. bovis BCG
strains over-expressing enzymes involved in mycolic acid
biosynthesis confirmed that only KasA over-expression
resulted in an increase in resistance to the indazole
sulphonamide. Direct binding of the indazole sulphonamide
to KasA was established through a chemoproteomics strategy.
In this approach, a tagged analogue of the compound was
linked to Sepharose beads and incubated with M. bovis BCG
extracts in the presence and absence of the unbound
indazole sulphonamide. Bound proteins were analysed by
mass spectrometry, revealing the specific binding of KasA to
the compound-derived beads. Finally, the molecular details
of the structure–activity relationship between KasA and the
indazole sulphonamide were determined through the
analysis of a co-crystal structure. Lead optimisation efforts of
this compound were pursued, but were rendered
unsuccessful owing to the detection of a mutagenic aniline
metabolite that could not be eliminated due to the limited
structure–activity relationship (SAR) space.79 This exemplifies
the copious efforts and resources expended in drug discovery
and provides one of an infinite number of reasons as to why
promising drug candidates fail to progress through the drug
discovery pipeline.
A success story can be represented by the imidazopyridines.
Through WGS, this compound class was shown to inhibit
QcrB,36 a constituent of the respiratory chain cytochrome bc1
complex. Lead optimisation of imidazopyridine analogues, led
to the discovery of Q203,34 which was also confirmed to target
QcrB and is now progressing through phase II clinical trials.1
Successful drug discovery therefore relies on a combination of
diverse methods, from the first instance of discovering an
inhibitory compound, to validation and informing future
developments. This ensures that only those compounds that
meet the stringent requirements of a drug progress through to
the clinic.
Conclusion
Over the past two decades, efforts in mycobacterial drug
discovery have increased exponentially, coinciding with the
availability of the Mtb genome sequence and the urgent
requirement of new drugs to combat MDR and XDR-TB. The
availability of extensive small molecule compound libraries,
along with the validation of a plethora of druggable targets,
have accelerated the discovery of potential inhibitors from
both drug-to-target and target-to-drug based screens.
Innovations in combining these two opposing directives are
anticipated to drive the rapid discovery and validation of new
targets with the concurrent delivery of vast diverse chemical
scaffolds for progression into drug candidates. Ultimately,
with the current global impetus towards Mtb drug discovery,
the future of TB drug discovery looks promising.
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